AbbVie and Simcere Zaiming Announce Partnership to Develop a …
5 days ago · NORTH CHICAGO, Ill. and SHANGHAI, Jan. 13, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) today announced an option to license agreement to develop SIM0500, an investigational new drug candidate. SIM0500 is currently in Phase 1 clinical trials in patients with relapsed or refractory multiple myeloma (MM), in both ...
AbbVie and Simcere Zaiming Announce Partnership to Develop a …
4 days ago · NORTH CHICAGO, Ill. and SHANGHAI, Jan. 13, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) today announced an option to...
JPM25: AbbVie pens $1B deal for Simcere’s phase 1 T-cell engager
4 days ago · The Big Pharma is handing Simcere an undisclosed upfront payment with the promise of up to $1.05 billion in milestones for the ... AbbVie pens $1B deal for Simcere’s phase 1 T-cell engager ...
AbbVie, Simcere Zaiming Partner to Develop Trispecific Antibody …
4 days ago · AbbVie and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd., entered an option to license agreement to develop SIM0500, an investigational new drug candidate in Phase 1 trials in relapsed or refractory multiple myeloma (MM), …
AbbVie And Simcere Zaiming Partner To Develop Innovative
4 days ago · As per the terms of the deal, Simcere Zaiming will get an initial payment from AbbVie and could earn upto $1.055 billion in option fees and milestone payments, along with royalties on net sales ...
AbbVie, Simcere Zaiming announce partnership to develop …
5 days ago · AbbVie and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group, announced an option to license agreement to develop SIM0500, an investigational new drug candidate. SIM0500 is currently ...
AbbVie and Simcere Zaiming to partner for trispecific antibody
2 days ago · Simcere Zaiming was founded in 2023 with a focus on oncology and is a subsidiary of Simcere Pharmaceutical Group Limited. In a separate development, AbCellera has expanded its existing partnership with AbbVie to include the discovery of …
Simcere Zaiming and AbbVie Announce Partnership to Develop a …
5 days ago · Shanghai China, and NORTH CHICAGO, Ill USA., Jan 13 2025-- Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) and AbbVie Inc. (NYSE: ABBV) today announced an option to license agreement to develop SIM0500, an investigational new drug candidate. SIM0500 is currently in Phase 1 clinical trials in patients with relapsed or refractory multiple myeloma (MM), in both ...
AbbVie and Simcere Zaiming Announce Partnership to Develop a …
4 days ago · Simcere Zaiming will receive an upfront payment from AbbVie and is eligible to receive option fees and milestone payments of up to $1.055B, as well as tiered royalties on net sales outside of the ...
AbbVie and Simcere to advance multiple myeloma candidate in …
2 days ago · AbbVie and Simcere Zaiming have announced a partnership worth over $1bn to develop an investigational drug candidate for multiple myeloma. The companies have entered into an option to licence agreement for Simcere Zaiming’s SIM0500, a trispecific antibody currently in phase 1 clinical development in the US and China for …
- Some results have been removed